INmune Bio Inc.
INMB
$1.21
-$0.01-0.82%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.97% | -9.15% | -20.87% | -47.07% | -18.26% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -94.92% | -86.62% | -76.44% |
| Total Other Non-Cash Items | 218.00% | 239.22% | 213.69% | 198.85% | 6.64% |
| Change in Net Operating Assets | -2,117.14% | -344.07% | -165.60% | -104.67% | -98.37% |
| Cash from Operations | 41.42% | 32.31% | -19.04% | -39.83% | -78.59% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 75.00% | 50.00% | 0.00% |
| Issuance of Common Stock | -33.49% | -2.36% | 0.64% | 147.41% | 4,220.65% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -14.04% | 51.62% | 43.16% | 462.17% | 486.39% |
| Foreign Exchange rate Adjustments | -293.22% | -170.98% | 188.04% | -4,900.00% | 51.28% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 130.32% | 125.65% | 29.57% | 113.76% | 73.34% |